Applicaiton Required

NSCLC-Radiogenomics

Medical image biomarkers of cancer promise improvements in patient care through advances in precision medicine. Compared to genomic biomarkers, image biomarkers provide the advantages of being a non-invasive procedure, and characterizing a heterogeneous tumor in its entirety, as opposed to limited tissue available for biopsy. We developed a unique radiogenomic dataset from a Non-Small Cell Lung Cancer (NSCLC) cohort of 211 subjects. The dataset comprises Computed Tomography (CT), Positron Emission Tomography (PET)/CT images, semantic annotations of the tumors as observed on the medical images using a controlled vocabulary, segmentation maps of tumors in the CT scans, and quantitative values obtained from the PET/CT scans. Imaging data are also paired with gene mutation, RNA sequencing data from samples of surgically excised tumor tissue, and clinical data, including survival outcomes. This dataset was created to facilitate the discovery of the underlying relationship between genomic and medical image features, as well as the development and evaluation of prognostic medical image biomarkers. For scientific inquiries relating to the data-set, please contact Drs. Sandy Napel (snapel@stanford.edu) or Sylvia K. Plevritis (sylvia.plevritis@stanford.edu).

Data and Resources

This dataset has no data

Additional Info

Field Value
Last Updated December 3, 2019, 14:29 (CST)
Created February 14, 2019, 10:19 (CST)

推薦資料集:


  • 20903-01-02-2 臺中市各項稅捐實徵淨額與預算數及上年同期比較-本月數

    Payment instrument Free
    Update frequency Irregular
    公務統計報表
  • 三環三線興建中捷運路線進度及說明

    Payment instrument Free
    Update frequency Irregular
    本計畫係由臺北都會區捷運路網已通車、興建中及規劃中之捷運路線所構成,建設完成後於本市境內建構而成之捷運路網。
  • 臺北市各區戶政事務所聯絡資訊

    Payment instrument Free
    Update frequency Irregular
    臺北市各區戶政事務所聯絡資訊
  • 國內個別選擇權契約交易概況明細表_NEW

    Payment instrument Free
    Update frequency Irregular
    國內個別選擇權契約交易概況明細表
  • 全體貨幣機構放款與投資(以原始取得成本衡量)

    Payment instrument Free
    Update frequency Irregular
    全體貨幣機構對企業、個人及政府部門之放款與證券投資(按性質別及對象別區分);以原始取得成本衡量。